Ricerc@Sapienza

Coronavirus disease 2019 (COVID-19) is characterized by
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) needing mechanical ventilation and intensive care
unit (ICU) treatment. In addition to lung disease, clinical
features of SARS-CoV-2 include myocardial damage and
ischemia-related vascular disease, which are associated
with a hypercoagulable state (e.g., high D-dimer levels)

One of the main prerequisite of a therapeutic drug is to overcome a series of physiological barriers and it to be less toxic for the human. To this aim, it is necessary to find a carrying vector able to enhance drug internalization and to improve its therapeutic efficacy. Presently, biocompatible and biodegradable nanoparticles (NPs) as some effective drug delivery devices, are widely studied.